DK3412660T3 - Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme - Google Patents
Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme Download PDFInfo
- Publication number
- DK3412660T3 DK3412660T3 DK17747622.3T DK17747622T DK3412660T3 DK 3412660 T3 DK3412660 T3 DK 3412660T3 DK 17747622 T DK17747622 T DK 17747622T DK 3412660 T3 DK3412660 T3 DK 3412660T3
- Authority
- DK
- Denmark
- Prior art keywords
- same
- pharmaceutical composition
- composition containing
- sulfonamide derivative
- sulfonamide
- Prior art date
Links
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016021053 | 2016-02-05 | ||
| PCT/JP2017/004278 WO2017135472A1 (ja) | 2016-02-05 | 2017-02-06 | スルホンアミド誘導体及びそれを含有する医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3412660T3 true DK3412660T3 (da) | 2020-11-30 |
Family
ID=59500204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17747622.3T DK3412660T3 (da) | 2016-02-05 | 2017-02-06 | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10562898B2 (da) |
| EP (1) | EP3412660B9 (da) |
| JP (1) | JP6820282B2 (da) |
| KR (1) | KR102870086B1 (da) |
| CN (1) | CN108699008B (da) |
| AU (1) | AU2017214589B2 (da) |
| CA (1) | CA3013433A1 (da) |
| DK (1) | DK3412660T3 (da) |
| EA (1) | EA036432B1 (da) |
| ES (1) | ES2856125T3 (da) |
| HU (1) | HUE053354T2 (da) |
| MX (1) | MX381970B (da) |
| PL (1) | PL3412660T3 (da) |
| PT (1) | PT3412660T (da) |
| TW (1) | TWI730042B (da) |
| WO (1) | WO2017135472A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331559B1 (en) | 1998-10-26 | 2001-12-18 | The Research Foundation Of State University Of New York At Stony Brook | Lipoic acid derivatives and their use in treatment of disease |
| TWI754702B (zh) | 2016-12-28 | 2022-02-11 | 德商Ucb製藥有限公司 | (氮雜)吲哚-和苯並呋喃-3-磺醯胺類 |
| US20210031012A1 (en) | 2018-01-26 | 2021-02-04 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| WO2019246455A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| DK3873884T3 (da) | 2018-10-30 | 2025-02-17 | Gilead Sciences Inc | 3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dion-derivater som alpha4beta7-integrinhæmmere til behandling af inflammatoriske sygdomme |
| PL3873605T3 (pl) | 2018-10-30 | 2025-03-03 | Gilead Sciences, Inc. | Związki hamujące integrynę alfa4beta7 |
| EP3873897B1 (en) | 2018-10-30 | 2024-08-14 | Gilead Sciences, Inc. | N-benzoyl-phenylalanine derivatives as alpha4beta7 integrin inhibitors for treating inflammatory diseases |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
| WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| TW202330490A (zh) | 2021-10-05 | 2023-08-01 | 日商Ea製藥股份有限公司 | 化合物或其藥學上所容許之鹽的製造方法 |
| CN120897744A (zh) | 2023-04-06 | 2025-11-04 | Ea制药株式会社 | 含有磺酰胺衍生物的自乳化组合物和自乳化药物递送系统 |
| WO2024210195A1 (ja) | 2023-04-06 | 2024-10-10 | Eaファーマ株式会社 | 炎症性腸疾患の治療用医薬組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| NZ518888A (en) | 1999-12-06 | 2004-02-27 | F | 4-pyridinyl-N-acyl-L-phenylalanines |
| WO2001056994A1 (en) | 2000-02-04 | 2001-08-09 | Biogen, Inc. | Integrin antagonists |
| NZ524122A (en) | 2000-08-18 | 2005-02-25 | Ajinomoto Kk | Phenylalanine derivatives useful as pharmaceutical agents |
| AU2003211560A1 (en) | 2002-02-20 | 2003-09-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
| JP4233353B2 (ja) | 2002-02-27 | 2009-03-04 | 田辺三菱製薬株式会社 | 医薬組成物 |
| WO2005000244A2 (en) * | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| WO2005061466A1 (ja) | 2003-12-22 | 2005-07-07 | Ajinomoto Co., Inc. | 新規フェニルアラニン誘導体 |
| EP1720839A1 (en) | 2004-02-10 | 2006-11-15 | Janssen Pharmaceutica N.V. | Pyridazinones as antagonists of a4 integrins |
| JP2007532681A (ja) | 2004-04-16 | 2007-11-15 | ジェネンテック・インコーポレーテッド | B細胞の枯渇を増大させる方法 |
| US8030328B2 (en) | 2005-05-20 | 2011-10-04 | Elan Pharmaceuticals, Inc. | Imidazolone phenylalanine derivatives |
| DK2842945T3 (da) * | 2012-04-24 | 2017-01-30 | Ea Pharma Co Ltd | Sulfonamid-derivat og medicinsk anvendelse deraf |
| DE102013206014A1 (de) * | 2013-04-05 | 2014-10-09 | Dürr Systems GmbH | Energiewandler-System und Baugruppen hierfür |
| BR112016009515B1 (pt) | 2013-10-29 | 2022-05-03 | EA Pharma Co., Ltd | Derivado de sulfonamida, composição farmacêutica, agente terapêutico ou um agente preventivo para doença inflamatória, e, inibidor de integrina a4ß7 |
-
2017
- 2017-02-06 JP JP2017565026A patent/JP6820282B2/ja active Active
- 2017-02-06 EA EA201891780A patent/EA036432B1/ru not_active IP Right Cessation
- 2017-02-06 DK DK17747622.3T patent/DK3412660T3/da active
- 2017-02-06 US US16/075,415 patent/US10562898B2/en active Active
- 2017-02-06 AU AU2017214589A patent/AU2017214589B2/en active Active
- 2017-02-06 CN CN201780009898.0A patent/CN108699008B/zh active Active
- 2017-02-06 EP EP17747622.3A patent/EP3412660B9/en active Active
- 2017-02-06 PL PL17747622T patent/PL3412660T3/pl unknown
- 2017-02-06 MX MX2018009459A patent/MX381970B/es unknown
- 2017-02-06 HU HUE17747622A patent/HUE053354T2/hu unknown
- 2017-02-06 WO PCT/JP2017/004278 patent/WO2017135472A1/ja not_active Ceased
- 2017-02-06 ES ES17747622T patent/ES2856125T3/es active Active
- 2017-02-06 PT PT177476223T patent/PT3412660T/pt unknown
- 2017-02-06 CA CA3013433A patent/CA3013433A1/en active Pending
- 2017-02-06 TW TW106103847A patent/TWI730042B/zh active
- 2017-02-06 KR KR1020187025805A patent/KR102870086B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI730042B (zh) | 2021-06-11 |
| TW201733991A (zh) | 2017-10-01 |
| KR20180104758A (ko) | 2018-09-21 |
| PL3412660T3 (pl) | 2021-04-19 |
| US20190040059A1 (en) | 2019-02-07 |
| HUE053354T2 (hu) | 2021-06-28 |
| AU2017214589B2 (en) | 2020-09-03 |
| MX381970B (es) | 2025-03-04 |
| JP6820282B2 (ja) | 2021-01-27 |
| EA201891780A1 (ru) | 2019-02-28 |
| PT3412660T (pt) | 2021-01-13 |
| AU2017214589A1 (en) | 2018-08-16 |
| EP3412660A1 (en) | 2018-12-12 |
| CN108699008A (zh) | 2018-10-23 |
| BR112018015855A2 (pt) | 2018-12-26 |
| WO2017135472A1 (ja) | 2017-08-10 |
| JPWO2017135472A1 (ja) | 2018-11-29 |
| CN108699008B (zh) | 2021-10-08 |
| KR102870086B1 (ko) | 2025-10-16 |
| EP3412660B9 (en) | 2021-04-14 |
| CA3013433A1 (en) | 2017-08-10 |
| EP3412660A4 (en) | 2019-07-10 |
| EA036432B1 (ru) | 2020-11-10 |
| US10562898B2 (en) | 2020-02-18 |
| MX2018009459A (es) | 2018-09-21 |
| EP3412660B1 (en) | 2020-11-18 |
| ES2856125T3 (es) | 2021-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3412660T3 (da) | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
| EP3493799A4 (en) | CANNABIS | |
| EP3513809A4 (en) | MEDICAL COMPOSITION | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| DK3655017T3 (da) | Farmaceutisk sammensætning | |
| IL256260B (en) | Treprostinil derivatives and compositions and uses thereof | |
| DK3603620T3 (da) | Liposomsammensætning og farmaceutisk sammensætning | |
| EP3641771A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| EP3493798A4 (en) | CANNABIS | |
| PT3500255T (pt) | Composições farmacêuticas oftálmicas e utilizações relacionadas com estas | |
| EP3454899C0 (en) | PHARMACEUTICAL COMPOSITION | |
| DK3494119T3 (da) | Forbindelser og sammensætninger og anvendelser deraf | |
| DK3399978T3 (da) | Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf | |
| DK3255042T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| EP3402470A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
| DK4023651T3 (da) | Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme | |
| DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin | |
| SMT202400478T1 (it) | Composizione farmaceutica | |
| EP3524250A4 (en) | PHARMACEUTICAL COMPOSITION |